Health & Fitness
Sat, May 12, 2012
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that Barry Wolfenson, the Companyas Executive Vice President for Global Marketing and Business Development will present a corporate overview and update at the Bank of America Merrill Lynch 2012 Health Care Conferencetaking place from Monday, May 14 - Thursday, May 17, 2012 at the Encore at the Wynn in Las Vegas, Nevada. The Companyas presentation will take place on Wednesday, May 16, 2012 at 1:00 p.m. local time.
To listen and view the presentation investors may visit the investor relations section of Derma Sciencesa website at [ www.dermasciences.com ]. An archived copy of the presentation will also be available on Derma Sciencesa website.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, BIOGUARD for infection prevention and TCC-EZa", a gold-standard treatment for diabetic foot ulcers.
For more information please visit [ www.dermasciences.com ].